Burke JP, Power C, Gorey TF, Flanagan F, Kerin MJ, Kell MR (2008) A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer. Europ J Surg Oncol : J Europ Soc Surg Oncol Br Assoc Surg Oncol 34(2):149–153

Article  CAS  Google Scholar 

Crispo A, Barba M, D’Aiuto G et al (2013) Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. BMC Cancer. https://doi.org/10.1186/1471-2407-13-15

Article  PubMed  PubMed Central  Google Scholar 

Burstein HJ, Curigliano G, Thürlimann B et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. gallen international consensus guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216–1235

Article  CAS  PubMed  Google Scholar 

Andre F, Ismaila N, Allison KH et al (2022) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. J Clin Oncol : Off J Am Soc Clin Oncol 40(16):1816–1837

Article  CAS  Google Scholar 

Piccart MJ, Hilbers FS, Bliss JM et al (2020) Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. J Clin Oncol 38(34):4120–4129

Article  CAS  PubMed  Google Scholar 

Visvanathan K, Fabian CJ, Bantug E et al (2019) Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol : Off J Am Soc Clin Oncol 37(33):3152–3165

Article  CAS  Google Scholar 

Chlebowski RT, Aragaki AK, Pan K (2021) Breast cancer prevention: time for change. JCO Oncol Pract. https://doi.org/10.1200/OP.21.00343

Article  PubMed  PubMed Central  Google Scholar 

Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among US women. Cancer Epidemiol Biomark Prev : Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 19(2):443–446

Article  CAS  Google Scholar 

Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS (2017) How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer 3:20

Article  PubMed  PubMed Central  Google Scholar 

Padamsee TJ, Hils M, Muraveva A (2021) Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women’s risk-reduction experiences. BMC Womens Health 21(1):157

Article  PubMed  PubMed Central  Google Scholar 

Chou R, Dana T, Blazina I, Daeges M, Jeanne TL (2016) Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive services task force. JAMA 316(19):2008–2024

Article  PubMed  Google Scholar 

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG (1999) American society of clinical oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17(6):1939–1939

Article  CAS  PubMed  Google Scholar 

Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 99(9):727–737

Article  CAS  PubMed  Google Scholar 

Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97(22):1652–1662

Article  CAS  PubMed  Google Scholar 

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M (2007) Twenty-year follow-up of the royal marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4):283–290

Article  CAS  PubMed  Google Scholar 

Cuzick J, Sestak I, Cawthorn S et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67–77

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M (2019) Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US preventive services task force. JAMA 322(9):868–886

Article  PubMed  Google Scholar 

Chlebowski RT (2015) IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol 16(1):7–9

Article  PubMed  Google Scholar 

Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784

Article  CAS  PubMed  Google Scholar 

Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13(9 Suppl):S5-17

Article  PubMed  Google Scholar 

Chlebowski RT, Aragaki AK, Anderson GL et al (2017) Low-fat dietary pattern and breast cancer mortality in the Women’s Health Initiative randomized controlled trial. J Clin Oncol : Off J Am Soc Clin Oncol 35(25):2919–2926

Article  CAS  Google Scholar 

Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886

Article  CAS  PubMed  Google Scholar 

Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548

Article  CAS  PubMed  Google Scholar 

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N (2002) The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 3(2):153–159

Article  PubMed  Google Scholar 

Prentice RL, Caan B, Chlebowski RT et al (2006) Low-fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative randomized controlled dietary modification trial. JAMA 295(6):629–642

Article  CAS  PubMed  Google Scholar 

Chlebowski RT, Aragaki AK, Anderson GL et al (2020) Dietary modification and breast cancer mortality: long-term follow-up of the women’s health initiative randomized trial. J Clin Oncol : Off J Am Soc Clin Oncol. https://doi.org/10.1200/JCO.19.00435

Article  Google Scholar 

Chlebowski RT, Kuller LH, Prentice RL et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chlebowski RT, Anderson GL, Aragaki AK et al (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324(4):369–380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rich-Edwards JW, Corsano KA, Stampfer MJ (1994) Test of the national death index and equifax nationwide death search. Am J Epidemiol 140(11):1016–1019

Article  CAS  PubMed  Google Scholar 

Owens DK, Davidson KW, Krist AH et al (2019) Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA 322(9):857–867

Article  PubMed  Google Scholar 

Dauphine C, Moazzez A, Neal JC, Chlebowski RT, Ozao-Choy J (2020) Single hormone receptor-positive breast cancers have distinct characteristics and survival. Ann Surg Oncol. https://doi.org/10.1245/s10434-020-08898-5

Article  PubMed